MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Sugammadex Hypersensitivity Study (Study P06042)

Phase 1
Completed
Conditions
Hypersensitivity
Interventions
Drug: Placebo run-in dose
Drug: Placebo
Drug: Sugammadex 4 mg/kg
Drug: Sugammadex 16 mg/kg
First Posted Date
2009-10-01
Last Posted Date
2019-01-30
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
448
Registration Number
NCT00988065

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Phase 2
Completed
Conditions
Measles
Rubella
Mumps
Varicella
Interventions
Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
First Posted Date
2009-09-29
Last Posted Date
2015-04-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1551
Registration Number
NCT00986232

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Phase 3
Completed
Conditions
Mumps
Rubella
Measles
Varicella
Interventions
Biological: ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)
First Posted Date
2009-09-28
Last Posted Date
2015-07-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
801
Registration Number
NCT00985166

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Phase 3
Completed
Conditions
Mumps
Rubella
Varicella
Measles
Interventions
Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
First Posted Date
2009-09-28
Last Posted Date
2015-11-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
3927
Registration Number
NCT00985153

Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)

Phase 3
Terminated
Conditions
Colitis, Ulcerative
Interventions
Biological: Infliximab
Drug: Prednisolone
Drug: Azathioprine
Drug: 5-aminosalicylic acid
First Posted Date
2009-09-25
Last Posted Date
2017-04-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
28
Registration Number
NCT00984568

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Phase 3
Completed
Conditions
Measles
Mumps
Rubella
Varicella
Interventions
Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
First Posted Date
2009-09-25
Last Posted Date
2015-08-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1913
Registration Number
NCT00984295

Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED)

Phase 3
Completed
Conditions
Muscle Relaxation
Interventions
Drug: Rocuronium bromide (Org 9426)
Drug: Sevoflurane
Drug: Propofol
First Posted Date
2009-09-25
Last Posted Date
2015-05-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
40
Registration Number
NCT00984633

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: MK-1006 DFC
Drug: MK-1006 FCT
First Posted Date
2009-09-18
Last Posted Date
2016-02-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
12
Registration Number
NCT00979459

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Phase 2
Completed
Conditions
Dyslipidemia
Interventions
Drug: anacetrapib
First Posted Date
2009-09-15
Last Posted Date
2015-05-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
408
Registration Number
NCT00977288

A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: sitagliptin phosphate
First Posted Date
2009-09-11
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00975052
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy